Lynn Johnson Langer replies:
I agree with many of the comments of Jan Rosier and David O'Connell. Students and entrepreneurs need to understand underlying principles and if and when it is necessary to create new approaches to solve problems that arise in startups. All of our courses in the Johns Hopkins University (JHU; Rockville, MD, USA) Master of Biotechnology Enterprise and Entrepreneurship are grounded in both academic theory and practical applications. As Rosier and O'Connell note, learners will have difficulties thinking outside the box if they do not first understand what is inside the box. Although I agree that understanding the science is critical, so is understanding established theories and practices of business. In the JHU course, we have seen examples where scientists unnecessarily try to create a new business process where an existing business practice will work; conversely, we've seen business people try to inappropriately push along a scientific idea that is not ready to leave the laboratory.
Each side needs to understand the limitations of the other. But, this is a leadership and management shortcoming, rather than a learning issue. Successful leaders need to know when to relinquish decision making to those with specialized knowledge, and our courses help ensure leaders recognize they can't do it all. Also, using the Rosier and O'Connell's regulatory example, many bio-derived products are so new and unique that the standard or current policies and guidelines at a regulatory agency may not apply. A startup's regulatory specialists, scientists and business people must work closely with regulatory agencies to create new ways to regulate never-before-seen products, such as biosimilars. In this case, thinking outside the box is critical.
As to the question of where such programs should be housed, my personal inclination is with some form of science-based programs, or at the least, a partnership between the science department and the business department. This is because the complexity and nature of biotech products require at the very least a fundamental understanding of the science and the environment in which scientists work. Scientists of all types tend to speak with a different vocabulary than business people. They interact with peers differently and prefer to be managed and lead in ways that are often unlike what business schools may present. The key problem is few professionals and academicians are trained in both science and business.
To the Editor:
An article in your January issue 1 highlights the struggles of the drug industry to engage with patients on social media. Today, patients take a more active role in their own care 2 In the present study, a search of the US National Center for Biotechnology Information's PubMed and Thomson Reuters' Web of Science literature databases using search terms from the studies mentioned above was carried out 1,2 (Supplementary Table 1 ). In addition, I reviewed bibliographical references cited in the details are available in the online version of the paper. a compound's true value and region-specific issues. Patients are keen to provide input for clinical trial design, outcome measures, recruitment materials and feedback to participants. Digital patient communities are one such avenue for involvement from those living with chronic illness as these platforms provide rapid, anonymous and convenient methods for hundreds or even thousands of patients to respond to questions over the course of mere days 8 . Successes to date include the rapid development of patient questionnaires and input on challenges inherent in clinical trial protocols. Key success factors include using a wide sample of patients, fostering a reciprocal relationship built on trust, providing feedback and continually assessing the value of incorporating patient views into existing processes 9 . Although high-tech platforms have advantages, such as speed, an in-person 'high-touch' approach may provide more subtle advantages, such as encouraging decision makers to put a face to the patient and think carefully about terminology 10 .
However, this approach may require additional time and resources, although time may be saved in avoiding protocol amendments or failed launches. Concerns about tokenism 5 are valid, and researchers should clarify that patients' views will be synthesized with other sources of input. Socalled representativeness can sometimes be used as an excuse not to listen to patients but may be overcome by using stratified recruitment or sample weighting to maximize generalizability. Commercial confidentiality can be maintained through tools, such as conjoint analysis, that might ask patients to choose from a range of hypothetical scenarios rather than respond to actual protocols.
Perhaps the biggest challenge, though, is cultural. Patients in 'fellowships' (i.e., a temporary period of employment and mutual learning of an engaged patient embedded within the organization with roles and responsibilities) could maximize the cultural change within a manufacturer, complementing the high-tech approach. Innovative companies should begin experimenting with integrating patient research partners into their decision-making process, building on the successes and failures of other actors in the healthcare system. Ultimately, those who can align their strategy, portfolio and execution with patient value will be the winners.
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To the Editor: A survey published in your pages several years ago 1 and a more recent review published elsewhere 2 indicate that there are >32,000 papers in the literature relating to genetically modified (GM) crops food and feed. Of those papers, only a subset relate specifically to human and environmental health risks. Although analyses of the literature have consistently concluded that the hazards associated with the use of GM crops are no greater than those for conventionally bred crops 2 , naysayers in the public debate continue to raise questions about the safety of these crops, citing a too-limited pool of original studies on GM crops food/ feed safety and a surfeit of studies in which outcomes may have been compromised because conflicts of interest (COIs) may have introduced bias and de-emphasized risks [3] [4] [5] .
Here, I present an assessment of original research papers addressing food/feed safety aspects of GM crops published in peerreviewed scientific journals (hereafter referred to as reports) with a view to defining the extent of literature related to food/feed safety and examining the issue of COIs.
The survey by Vain 1 published 9 years ago indicated that by 2006, >31,848 reports had Conflict of interests and evidence base for GM crops food/feed safety research
